BGNE Stock Recent News

The 'Undercovered' Dozen series highlights 12 lesser-covered stocks weekly, providing investment ideas and sparking community discussion on their potential. Graham Corporation and Legal & General Group Plc are recommended as buys due to strong balance sheets, strategic growth, and favorable market conditions. Butterfly Network, Hudson Pacific Properties, and B&G Foods are rated as holds, with potential for growth but facing significant challenges and uncertainties.

BeiGene, Ltd., soon to be BeOne Medicines, is a global oncology company with a strong focus on innovative cancer treatments, particularly Brukinsa and Tevimbra. Brukinsa, a BTK inhibitor, has shown impressive revenue growth and market share gains, with significant potential for future expansion and revenue generation. Tevimbra, while facing intense competition, shows promise with recent FDA approvals and ongoing trials targeting various cancers.

BeiGene Ltd.  ONC stock is trading lower after the company reported mixed first-quarter 2025 financial results on Wednesday.

The headline numbers for BeiGene (ONC) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines, Ltd., today announced financial results and corporate updates from the first quarter 2025. “We delivered another exceptional quarter, achieving our first quarter of GAAP profitability with continued global revenue growth. In the U.S., BRUKINSA remains the leader in new chronic lymphocytic leukemia (CLL) patient starts across all line.

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC's (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR pe.

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investo.

RBC Capital initiated coverage of BeiGene with an Outperform rating and $312 price target. RBC sees a path to robust revenue growth driven by Brukinsa's market dominance and high-value follow-on assets in the hematology-oncology space, the analyst tells investors in a research note. BeiGene's oncology pipeline, proven R&D capabilities, and a fast to-execution mindset are key ingredients for the company's emerging position as a global oncology powerhouse that could drive market capitalization expansion, the firm says.

BeiGene Ltd ONC on Thursday announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer.

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer. The Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302 trial (NCT04746924) based on its findings as part of a pre.